Navigation Links
Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
Date:3/30/2011

STEWARTVILLE, Minn., March 30, 2011 /PRNewswire/ -- Rochester Medical Corporation (Nasdaq: ROCM) announced that the shareholders of Fornix BioSciences N.V. today approved the previously announced sale of Laprolan B.V. its Medical Supplies Division and wholly owned subsidiary to Rochester Medical Corporation.

Rochester Medical expects the transaction to close in the near term, and under the terms of the Share Purchase Agreement between Rochester Medical and Fornix, be deemed retroactive to January 1, 2011.  For more information regarding this transaction please refer to the Company's January 12, 2011 press release.

This press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, but are not limited to, statements about the expected completion of the acquisition of Laprolan.  Such statements are based on currently available information, operating plans and management's expectations about future events and trends.  Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2010.  Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made.  The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Rochester Medical Corporation develops, manufactures, and markets latex-free disposable medical catheters and devices for urological an
'/>"/>

SOURCE Rochester Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
2. Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders
3. Caraco Announces Merger Agreement with Sun Pharma; Caraco Public Shareholders to Receive $5.25 Cash per Share
4. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
5. Amarin Provides 2010 Year-End Review to Shareholders
6. BD Announces Webcast of Annual Meeting of Shareholders
7. Penwest Pharmaceuticals Shareholders Approve Merger With Subsidiary of Endo Pharmaceuticals
8. Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010
9. China Sky One Medical, Inc. Reports Outcome of Annual Meeting of Shareholders
10. Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
11. United American Healthcare Corporation Announces Results of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced today that ... approximately $3.3 million at a price of $0.30 per ... focused investor. Each unit consists of one common share ... warrant. Each whole warrant entitles the holder to acquire ... a period of five years from closing.  ...
(Date:11/26/2014)... Texas , Nov. 26, 2014 ... today announced the completion of previously announced concurrent ... million.  After fees and estimated offering expenses, Lexicon ... the transactions.  The transactions consisted of: ... common stock, pursuant to a registration statement that ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Therapeutics (Nasdaq: NKTR ) today reported its financial ... 2010. Cash, cash equivalents, and short-term investments ... at December 31, 2010 does not include proceeds of $220.4 ... in January 2011.   Revenue for the fourth ...
... 2011 OncoMed Pharmaceuticals, Inc., a company developing novel ... publication of preclinical data demonstrating that its lead candidate, ... frequency when administered alone or in combination with chemotherapy ... mutations.  This study was published in the March 1, ...
Cached Medicine Technology:Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results 7OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 2OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 3OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 4OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status 5
(Date:11/28/2014)... Written and narrated by award winning author Dr. James ... Happiest Man In the World: Life Lessons From a Cultural ... Project C.U.R.E. came to be. , Raised in the Boise ... Richard W. Jackson, Dr. Jackson exceeded his goal of being ... he wasn’t happy. Prompted by this realization, James and his ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Not only ... create products free of petroleum, parabens and other cancer-causing ... that fund research, education and awareness programs that help ... staff and owners have raised an incredible, record-breaking contribution ... the Cure, sales of the Sweet Red Rose Whip ...
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
(Date:11/28/2014)... Miami, FL (PRWEB) November 28, 2014 Lice ... service areas of its in-home head lice service for ... location in the center of Coral Gables on Pone De-leon ... in Bay Harbor Islands that service Miami-Dade & Broward. ... physical salon in South Florida which has been treating families ...
(Date:11/28/2014)... 2014 Schools like Centra Rivermont ... quality commercial playground equipment to its students. That ... supply an affordable play structure at its mental ... Centra provides comprehensive programs for children who are ... services. They have served the needs of ...
Breaking Medicine News(10 mins):Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 3
... University and Harvard University have collaboratively developed a new theoretical ... sequences, even though there are many obstacles in the way ... in the scientific journal Nature Physics . , In ... so that different cells carry out the right tasks at ...
... important tasks of the immune system is to identify what ... then the body,s own structures will be attacked, the result ... mellitus type 1 or multiple sclerosis. The only way to ... that turn against the body,s own tissue in other ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced that shareholders ... of Tepnel by Gen-Probe by the requisite majorities at Court ... of Tepnel shareholders voted in favor of the acquisition, which ... as a "scheme of arrangement" under English law. The ...
... Probiotic Works Naturally to Restore Oral HealthCHICAGO, March ... and Butler(R) brand products, has introduced GUM(R) PerioBalance(TM), ... for oral health. GUM(R) PerioBalance(TM) is available online ... GUM(R) PerioBalance(TM) e-store ( www.periobalance.com ) and at ...
... Health Segment Increases Annual RevenueLOVELAND, Colo., March 16 ... ("Heska" or the "Company") today reported financial results ... December 31, 2008, and year ended December 31, ... , "The poor economic environment had an impact ...
... led by Clifford Goodman, PhD, at the NCCN 14th Annual ... Cancer Care." The panel of experts tackled the spectrum of ... benefit to patients of some of the latest cancer treatments ... Oncology is an area of rapid growth, both in terms ...
Cached Medicine News:Health News:Important new model shows how proteins find the right DNA sequences 2Health News:Dendritic cells ensure immune tolerance 2Health News:Dendritic cells ensure immune tolerance 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 2Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 4Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 2Health News:New Probiotic Supplement Helps Consumers Fight Unhealthy Teeth and Gums 3Health News:Heska Announces Q4 and Annual 2008 Results 2Health News:Heska Announces Q4 and Annual 2008 Results 3Health News:Heska Announces Q4 and Annual 2008 Results 4Health News:Heska Announces Q4 and Annual 2008 Results 5Health News:Heska Announces Q4 and Annual 2008 Results 6Health News:Heska Announces Q4 and Annual 2008 Results 7Health News:Heska Announces Q4 and Annual 2008 Results 8Health News:Heska Announces Q4 and Annual 2008 Results 9Health News:Heska Announces Q4 and Annual 2008 Results 10Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 2Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 3Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 4Health News:Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference 5
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
... The Attain™ Deflectable Catheter - designed ... using a single catheter. Steerablility - Create ... procedure with a single, steerable guide catheter. ... desired shape to address each patient's unique ...
Attain LV Leads. Navigate minimally angled veins with little to moderate tortuosity....
... The Hancock® II bioprosthesis from ... years of proven clinical experience. ... the freedom from structural valve ... and mitral bioprostheses is substantially ...
Medicine Products: